On the recordJuly 25, 2019
CREATES addresses a tactic the company that makes Revlimid, Celgene, uses to deny generic companies access to samples of Revlimid.
Source
congress.govEditor's note · Context
Discussing the CREATES Act to improve access to generic medications.
Share
More from Jim Jordan
Sep 3, 2025
We are more concerned frankly as Americans about the limits the DSA (Digital Services Act) and the Online Safety Act in the UK put on Americans’ First Amendment rights.
Apr 16, 2026
I thank the chairman of the Immigration Integrity, Security, and Enforcement Subcommittee for the great work he does on this issue and a host of others. Mr. Speaker, understand the Democrats' plan. It is as straightforward as you can…
Oct 14, 2025
Your misdeeds were so flagrant that the Justice Department’s Office of Professional Responsibility confirmed to the Committee in November 2024 that it had opened an inquiry into the tactics of your office.
Apr 30, 2026
This is not the outcome that any of us wanted for the FISA 702 program, but here we are. The 702 program is incredibly important for protecting our national security and advancing our interests abroad. This temporary extension will ensure…
Other voices in this conversation
